Showing results (61-70 of 89) with videos related to
Sort By:
Pageof 9
Medical and Pediatric Oncology|January 1, 1979
Vincristine and prednisone vs vincristine, L-asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in childrenJ Herson, K A Starling, P G Dyment, et al.NCI Monographs : a Publication of the National Cancer Institute|January 1, 1988
Phase III trial of irradiation plus chemotherapy for patients with hepatic metastases and hepatoma: experience of the Northern California Oncology GroupM A Friedman, T L Phillips, J F Hannigan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1983
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology GroupM M Koretz, P M Jackson, F M Torti, et al.Journal of the National Cancer Institute|August 1, 1984
Cancer mortality in relatives of retinoblastoma patientsL C Strong, J Herson, C Haas, et al.Cancer|September 1, 1980
Comparison of prednisolone, vincristine, methotrexate and 6-mercaptopurine vs. 6-mercaptopurine and prednisone maintenance therapy in childhood acute leukemia: a Southwest Oncology Group StudyD H Berry, D J Fernbach, J Herson, et al.Medical and Pediatric Oncology|January 1, 1979
Long-term survival in childhood acute leukemia: "late" relapsesV J Land, D H Berry, J Herson, et al.Gynecologic Oncology|April 1, 1983
Role of "third-look" laparotomy in the guidance of ovarian cancer treatmentL J Copeland, J T Wharton, F N Rutledge, et al.Obstetrics and Gynecology|April 1, 1985
Surgical management of irradiation-induced small bowel damageS T Smith, J C Seski, L J Copeland, et al.Cancer|November 15, 1983
Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California Oncology Group and the Japanese Gastric Cancer Chemotherapy GroupM A Friedman, M Ogawa, S K Carter, et al.Urology|April 11, 2001
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancerR C Bergan, D H Waggle, S K Carter, et al.Pageof 9